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Rat hepatocytes were maintained in monolayer culture for 20 h in the presence of 10% (v/v) new-born calf 
serum and then for a further l-24 h in serum-free medium containing 2 g bovine serum albumin/l. The 
specific binding of human lzSI-LDL to two distinct sites was then measured at 4°C. Binding to site 1 was 
displaced by dextran sulphate while that to site 2 was not. The presence of l-100 nM insulin for 24 h in 
the second incubation significantly increased binding to site 1. Significant increases were also seen when 
cells were incubated with 10 nM insulin for 1 h. No significant effects of insulin on binding to site 2 were 
observed. In contrast, 10 nM-1 PM dexamethasone decreased binding to both sites. The effects of these 
hormones were mutually antagonistic. 
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1. INTRODUCTION 
The liver has an important function in removing 
LDL from the circulation. The cholesterol con- 
tained in these particles can then be re-secreted in 
VLDL or HDL components. Alternatively, the 
cholesterol can be secreted into the bile directly, or 
after its conversion to bile salts. These latter pro- 
cesses provide the major route of cholesterol excre- 
tion since the reabsorption of cholesterol and bile 
acids from the intestine is incomplete. 
The uptake of LDL by the liver is mainly by en- 
docytosis via a specific receptor similar to that 
which has been described in a variety of cultured 
cell types [l]. As such, the binding is specific for 
apolipoprotein (apo) B and apoE; it can be in- 
hibited by the modification of lysine and arginine 
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residues of the apolipoprotein; it is Ca2+-de- 
pendent and LDL can be displaced by heparin or 
dextran sulphate. Specific binding sites other than 
this ‘classic’ LDL receptor have been described on 
isolated liver membranes, and for hepatocytes in 
culture. This site (or sites) generally do not have an 
absolute requirement for Ca2+ [2-lo]. Binding of 
LDL can also be detected in livers of patients suf- 
fering from homozygous familial hyper- 
cholesterolaemia where the classic receptor should 
be absent [7,8,11]. 
There is considerable interest in the factors that 
may regulate LDL uptake by the liver since this is 
a major route whereby LDL is eliminated from the 
circulation. This is important because of the 
association of high plasma LDL levels with in- 
creased risk of developing atherosclerosis. 
However, our present knowledge of the 
mechanisms that control the binding, uptake and 
degradation of LDL by the liver is relatively 
limited. It is known that incubating a human 
hepatoma cell line (Hep G2) with ‘heavy’ HDL 
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(Q = 1.16-l .20 g/ml) increased the binding of 
human ‘251-LDL [12]. Similarly, preincubating rat 
hepatocytes with human HDLj, but not HDL2, in- 
creased the binding and degradation of human 
LDL by what appeared to be the classic LDL 
receptor [9,10,13]. Porcine HDL (e = 1.12- 
1.16 g/ml) has also been shown to increase the 
degradation, but apparently not the uptake, of 
homologous LDL by porcine hepatocytes [6]. In 
fibroblasts preincubation with LDL has been 
shown to markedly decrease subsequent binding 
and uptake of LDL [14]. However, in both Hep G2 
cells [ 121 and hepatocytes [ 10,131 this effect is 
much less pronounced. This difference probably 
relates to the role of the liver in actively removing 
LDL cholesterol from the circulation. 
In terms of hormonal control, it is known that 
pharmacological doses of 17cz-ethinyloestradiol 
cause a marked decrease in plasma cholesterol, 
resulting from an up-regulation of LDL receptors 
in the liver [15-171. Insulin enhances the degrada- 
tion of LDL by fibroblasts by increasing the 
number of LDL receptors [18]. In contrast, cor- 
tisol decreased the uptake and degradation of ‘251- 
LDL by human fibroblasts and smooth muscle 
cells without altering the binding of LDL to the 
cells [ 191. 
The present work was undertaken to determine 
the effects of pre-incubation of rat hepatocytes 
with insulin and a glucocorticoid (dexamethasone) 
on the ability of the cells to bind human ‘251-LDL 
to two distinct sites. Site 1 was the classic LDL site 
for which binding was Ca*+-dependent and it was 
displaced by dextran sulphate. Site 2 was defined 
as the residual specific binding that was not 
displaced by dextran sulphate. This binding 
showed relatively little dependency on Ca*+ [9]. 
2. MATERIALS AND METHODS 
Hepatocytes from male Wistar rats were 
prepared and cultured on collagen-coated tissue 
culture dishes [9,10,20]. The techniques used for 
preparing human ‘2SI-LDL, measuring specific 
binding at 4°C to sites 1 and 2 and determination 
of protein have been described [9]. 
3. RESULTS 
The hepatocyte cultures were incubated for an 
160 
initial 20 h in medium containing 10% (v/v) 
newborn calf serum in order to stabilize the cells 
and to provide a suitable model for measuring the 
effects on LDL binding [lo]. The medium was then 
changed and the serum was replaced by 2 g fatty 
acid-poor bovine serum albumin/l. After a further 
1 h incubation cells were transferred to fresh 
albumin containing medium in the presence or 
absence of the indicated hormones. Hepatocytes 
have previously been shown to be responsive to in- 
sulin and dexamethasone under such conditions 
[20,21]. 
The incubation of hepatocytes for 24 h in 
serum-free medium in this work caused a signifi- 
cant increase in specific binding to site 1, whereas 
that to site 2 remained relatively constant (fig.1). 
The presence of l-100 nM insulin for 24 h 
significantly increased the binding of LDL to site 
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Fig. 1. Effect of time in culture on the specific binding of 
LDL to rat hepatocytes. Rat hepatocytes were cultured 
for 20 h in the presence of 10% (v/v) newborn calf 
serum and then up to a further 24 h in serum-free 
medium containing 2 g bovine serum albumin/l. The 
specific binding of ‘251-LDL to sites 1 (A , A) and 2 
( q , n ) in the absence (A , 0) and presence (A , n ) of 
10 nM insulin is shown. 
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Fig.2. Effects of insulin and dexamethasone on the specific binding of LDL to rat hepatocytes. Rat hepatocytes were 
cultured for 20 h in the presence of 10% (v/v) newborn calf serum and then for a further 24 h in serum-free medium 
containing 2 g bovine serum albumin/l. The specific binding of lZSI-LDL to sites 1 (A) and 2 (0) was measured in the 
absence and presence of different concentrations of (A) insulin and (B) dexamethasone. Results are means f SE with 
the number of independent experiments hown in parentheses and they are expressed relative to binding in the absence 
of added hormone. (*) Values statistically different from control. 
1 (fig.2A). This effect with 10 nM insulin was also 
observed after 1 h on site 1 (fig.1) and in four in- 
dependent experiments binding was 21 f 6% 
higher 0, < 0.05) than for controls. Although there 
appeared to be an increase in binding to site 2 in 
the presence of insulin this did not reach statistical 
significance at any time point or concentration 
probably because of the variability of the effect. In 
two experiments where cells were incubated with 
1 nM insulin for 24 h increases in binding to site 2 
of 441 and 545% were observed. The reason for 
the discrepancy between these and the other 6 ex- 
periments is unknown and they have been omitted 
from fig.2A. 
Dexamethasone (10 nM-1 PM) decreased LDL 
binding to sites 1 and 2 and the effect seemed 
greater on site 1 in all experiments. These effects of 
dexamethasone did not become apparent until 
12-24 h of incubation (not shown). Insulin was 
able to antagonise the effects of dexamethasone on 
site 1 such that relative binding in the presence of 
100 nM dexamethasone of 42 f 3% was increased 
to 57 + 5% when 1 nM insulin was also present 
(n = 8, p < 0.05). Under similar conditions, 
binding to site 2 appeared to increase from 76 f 5 
to 88 + 8%, although this was not statistically 
significant. 
4. DISCUSSION 
The results indicate for the first time that insulin 
and a glucocorticoid have direct effects on the 
binding of LDL to hepatocytes. Insulin increases 
whereas dexamethasone decreases binding. The 
mechanisms which produce these changes have not 
yet been elucidated. However, the insulin effect 
was seen between 1 and 24 h of incubation, 
whereas the dexamethasone effect only became ap- 
parent after about 12 h. The changes are most con- 
sistent for site 1, which has the properties of the 
classic LDL receptor, and the effects of the two 
hormones were mutually antagonistic. Our 
findings on the effects of insulin are in contrast to 
those of Jensen et al. [22] who found no effect on 
the uptake of human LDL by rat hepatocytes. 
However, our experimental system was significant- 
ly different from theirs in that they preincubated 
hepatocytes in the presence of 10% lipoprotein- 
deficient foetal calf serum and this was also pre- 
sent during the incubation with insulin. Further- 
more, unlike these workers, we found no 
significant effect of insulin on cell density as 
reflected by the amount of cell protein recovered 
from each tissue culture dish. 
Whether the changes in binding to the 
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hepatocytes that are produced are paralleled by 
changes in the uptake and degradation remains to 
be firmly established however, preliminary 
evidence suggests that this is so (Brown, Salter and 
Brindley, unpublished). 
The reported effects of insulin and dex- 
amethasone on LDL binding could have important 
implications for understanding the changes in 
lipoprotein metabolism that occur in various 
diseases. For example, diabetes and stress are often 
considered to be risk factors for the development 
of premature atherosclerosis. The present results 
indicate that the decreased binding of LDL by the 
liver, which would result from an increased action 
of glucocorticoids relative to insulin, might also 
decrease the removal of LDL from the blood. The 
consequent increase in circulating LDL could ac- 
count for part of the increased atherosclerotic risk 
associated with these conditions. 
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